Abstract:The biological impact of NAD boosting on aging and cellular senescence is not completely understood. It appears that NAD is necessary for senescent cell function. Therefore, NAD boosting may increase senescence‐induced dysfunction. Combination of NAD boosters with senolytic therapy may be a promising approach to improve NAD‐targeted interventions, potentially benefiting age‐related diseases. However, no studies on this combination therapy have been reported yet. The geroscience hypothesis proposes that addressing the biology of aging could directly prevent the onset or mitigate the severity of multiple chronic diseases. Understanding the interplay between key aspects of the biological hallmarks of aging is essential in delivering the promises of the geroscience hypothesis. Notably, the nucleotide nicotinamide adenine dinucleotide (NAD) interfaces with several biological hallmarks of aging, including cellular senescence, and changes in NAD metabolism have been shown to be involved in the aging process. The relationship between NAD metabolism and cellular senescence appears to be complex. On the one hand, the accumulation of DNA damage and mitochondrial dysfunction induced by low NAD+ can promote the development of senescence. On the other hand, the low NAD+ state that occurs during aging may inhibit SASP development as this secretory phenotype and the development of cellular senescence are both highly metabolically demanding. However, to date, the impact of NAD+ metabolism on the progression of the cellular senescence phenotype has not been fully characterized. Therefore, to explore the implications of NAD metabolism and NAD replacement therapies, it is essential to consider their interactions with other hallmarks of aging, including cellular senescence. We propose that a comprehensive understanding of the interplay between NAD boosting strategies and senolytic agents is necessary to advance the field.

Targeting NAD Metabolism for the Therapy of Age-Related Neurodegenerative Diseases

Nicotinamide Forestalls Pathology and Cognitive Decline in Alzheimer Mice: Evidence for Improved Neuronal Bioenergetics and Autophagy Procession

Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule

NAD+ Deficiency Is a Common Central Pathological Factor of a Number of Diseases and Aging: Mechanisms and Therapeutic Implications

Nicotinamide Mononucleotide: A Promising Molecule for Therapy of Diverse Diseases by Targeting NAD Plus Metabolism

NAD metabolism: Role in senescence regulation and aging

NAD+ in Alzheimer’s Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo

NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential

Nad(+) Metabolism and Nad(+)-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases

NAD+ metabolism and its roles in cellular processes during ageing

Pathobiochemistry of Aging and Neurodegeneration: Deregulation of NAD+ Metabolism in Brain Cells

Nicotinamide Phosphoribosyltransferase as a Key Molecule of the Aging/Senescence Process

The therapeutic perspective of NAD+ precursors in age-related diseases

NAD+ metabolism and therapeutic strategies in cardiovascular diseases

Implications of altered NAD metabolism in metabolic disorders

Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan

[Research progress on nicotinamide phosphoribosyl transferase involved in aging and age-related diseases].

NAD+ homeostasis in health and disease

Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing

The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions

Research advances in the function and anti-aging effects of nicotinamide mononucleotide